Meeting of the HMA-EMA group focused on AI with industry stakeholders - February 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 4 February 2026, 10:00 (CET) to 4 February 2026, 11:30 (CET)

Human medicines European public assessment report (EPAR): Zyprexa, olanzapine, Date of authorisation: 27/09/1996, Revision: 47, Status: Authorised

Quality Innovation Group (QIG): Listen and learn focus group meeting on sustainability, Online, European Medicines Agency, Amsterdam, the Netherlands, from 4 March 2026 to 5 March 2026

Human medicines European public assessment report (EPAR): Aumseqa, Aumolertinib, Date of authorisation: 12/02/2026, Status: Authorised

EMA multi-stakeholder workshop on supporting innovation in cardiovascular medicines and medical devices in the EU, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 1 July 2026, 13:00 (CEST) to 2 July 2026, 16:00 (CEST)

Human medicines European public assessment report (EPAR): Spikevax (previously COVID-19 Vaccine Moderna), COVID-19 mRNA vaccine, Date of authorisation: 06/01/2021, Revision: 61, Status: Authorised

Human medicines European public assessment report (EPAR): Nustendi, bempedoic acid,ezetimibe, Date of authorisation: 27/03/2020, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Nilemdo, bempedoic acid, Date of authorisation: 01/04/2020, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Alecensa, alectinib, Date of authorisation: 16/02/2017, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Cometriq, cabozantinib, Date of authorisation: 21/03/2014, Revision: 31, Status: Authorised